Joining as chief creative officer, Florence has “deep pharma and consumer chops.”
The deal is a major development coming on the heels of JPA’s acquisition of BioCentric, Inc. a clinical communications company based in greater Philadelphia and Switzerland (May 2024), and True North Solutions last fall, as well as the launch of GRETEL Trails, JPA’s proprietary AI-powered insight engine and chatbot, last summer.
Innovent Biologics’ dual GLP-1/glucagon receptor agonist mazdutide is also being developed for chronic weight management. China’s regulator accepted Innovent’s drug application for this indication in February 2024.
GSK is seeking to relaunch Blenrep after its market withdrawal in 2022. The pharma is eyeing a second-line niche for the antibody-drug conjugate in the treatment of relapsed or refractory multiple myeloma.
“Empowering Health Discovery: Fueling experiences with patients, caregivers, and HCPs on their health knowledge journey” offers a detailed exploration of topics including shifts in today’s media landscape, media investment patterns, and navigating future changes.
After a long and challenging journey for its stem cell therapy NurOwn, BrainStorm Cell Therapeutics has aligned with the FDA on the parameters of a Phase IIIb ALS trial that is expected to begin by the end of 2024.